

Amendments to the Claims

This Listing of the Claims replaces all prior Listings of the Claims

1. (Currently amended) A method for formulating a deaggregated polyene antibiotic, said method comprising the steps of :
 - (a) dissolving a polyene antibiotic and a poly(ethylene glycol)-phospholipid in a solvent to produce a solution;
 - (b) evaporating the solvent from the solution of step (a) under conditions of temperature from 26°C to 40°C and conditions of pressure from 100 mm to 300 mm mercury to produce a drug-polymer film;
 - (c) adding water at a temperature from 25°C to 80°C to the drug-polymer film of step (b) and mixing vigorously,

whereby micelles comprising the deaggregated polyene antibiotic and poly(ethylene glycol)-phospholipid are formed.

2. (Original) The method of claim 1 wherein the poly(ethylene glycol)-phospholipid is monomethoxy poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine.
3. (Original) The method of claim 1 wherein the polyene antibiotic is Amphotericin B (AmB).
4. (Original) The method of claim 1 wherein the solvent is methanol or chloroform:methanol (1:2).

5. (Original) The method of claim 4 wherein the conditions for evaporating the solvent are 40°C and 300 mm mercury.
6. (Original) The method of claim 3 wherein in step (c) water is added at a temperature from 40°C to 75°C.
7. The method of claim 2 wherein the molecular weight of the poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine is about 5000 to about 12,000.
8. (Original) The method of claim 3 wherein the poly(ethylene glycol)-phospholipid is monomethoxy poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine and the molar ratio of AmB to poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine to AmB is from about 0.75:1 to about 10:1.
9. (Original) The method of claim 8 wherein the molar ratio of poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine to AmB is from 1:1 to 3:1.
10. (Original) The method of claim 9 wherein the molar ratio of poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine to AmB is 1:1 to 1.5:1.
11. (Original) The method of claim 1 further comprising the step of freeze-drying the micelles after step (c).
12. (Currently amended) A composition comprising micelles consisting essentially of Amphotericin B (AmB) and poly(ethylene glycol)-1,2-di-stearoyl-phosphatidyl ethanolamine (mPEG-DSPE) in a molar ratio of mPEG-DSPE:AmB of from 1:1 to 3:1.

Application No. 10/687,558
Filed October 15, 2007
Response to Office Action Dated January 25, 2007
Amendment filed July 25, 2007

13. (Original) The composition of claim 12 further comprising a pharmaceutically acceptable carrier.
14. (Original) The composition of claim 13 wherein the pharmaceutically acceptable carrier is a dextrose solution.
15. (New) The composition of claim 12, wherein the AmB is deaggregated.